Homocystamide Conjugates of Human Serum Albumin as a Platform to Prepare Bimodal Multidrug Delivery Systems for Boron Neutron Capture Therapy

Boron neutron capture therapy is a unique form of adjuvant cancer therapy for various malignancies including malignant gliomas. The conjugation of boron compounds and human serum albumin (HSA)—a carrier protein with a long plasma half-life—is expected to extend systemic circulation of the boron comp...

Full description

Saved in:
Bibliographic Details
Published inMolecules (Basel, Switzerland) Vol. 26; no. 21; p. 6537
Main Authors Popova, Tatyana, Dymova, Maya A., Koroleva, Ludmila S., Zakharova, Olga D., Lisitskiy, Vladimir A., Raskolupova, Valeria I., Sycheva, Tatiana, Taskaev, Sergei, Silnikov, Vladimir N., Godovikova, Tatyana S.
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 29.10.2021
MDPI
Subjects
Antineoplastic Agents - chemical synthesis
Antineoplastic Agents - chemistry
Antineoplastic Agents - therapeutic use
Biodistribution
Boron
Boron Compounds - chemical synthesis
Boron Compounds - chemistry
Boron Compounds - therapeutic use
boron delivery agents
Boron Neutron Capture Therapy
boronated albumin theranostic
Brain cancer
Cancer therapies
Cell Line, Tumor
Cell Proliferation - drug effects
Cell Survival - drug effects
Chemotherapy
conjugate
Cytotoxicity
Drug Delivery Systems
Drug Screening Assays, Antitumor
Drugs
Fluorine
Glioma
Homocysteine - analogs & derivatives
Homocysteine - chemistry
Humans
Hyperglycemia
in vitro efficacy evaluation
Magnetic resonance imaging
Molecular Structure
Proteins
Radiation
Serum Albumin, Human - chemistry
thenoyltrifluoroacetone
Tumors
conjugate
boron neutron capture therapy
thenoyltrifluoroacetone
colony forming assay
boronated albumin theranostic
irradiated by epithermal neutron flux
in vitro efficacy evaluation
boron delivery agents
Online AccessGet full text

Cover

Abstract Boron neutron capture therapy is a unique form of adjuvant cancer therapy for various malignancies including malignant gliomas. The conjugation of boron compounds and human serum albumin (HSA)—a carrier protein with a long plasma half-life—is expected to extend systemic circulation of the boron compounds and increase their accumulation in human glioma cells. We report on the synthesis of fluorophore-labeled homocystamide conjugates of human serum albumin and their use in thiol-‘click’ chemistry to prepare novel multimodal boronated albumin-based theranostic agents, which could be accumulated in tumor cells. The novelty of this work involves the development of the synthesis methodology of albumin conjugates for the imaging-guided boron neutron capture therapy combination. Herein, we suggest using thenoyltrifluoroacetone as a part of an anticancer theranostic construct: approximately 5.4 molecules of thenoyltrifluoroacetone were bound to each albumin. Along with its beneficial properties as a chemotherapeutic agent, thenoyltrifluoroacetone is a promising magnetic resonance imaging agent. The conjugation of bimodal HSA with undecahydro-closo-dodecaborate only slightly reduced human glioma cell line viability in the absence of irradiation (~30 μM of boronated albumin) but allowed for neutron capture and decreased tumor cell survival under epithermal neutron flux. The simultaneous presence of undecahydro-closo-dodecaborate and labeled amino acid residues (fluorophore dye and fluorine atoms) in the obtained HSA conjugate makes it a promising candidate for the combination imaging-guided boron neutron capture therapy.
AbstractList Boron neutron capture therapy is a unique form of adjuvant cancer therapy for various malignancies including malignant gliomas. The conjugation of boron compounds and human serum albumin (HSA)—a carrier protein with a long plasma half-life—is expected to extend systemic circulation of the boron compounds and increase their accumulation in human glioma cells. We report on the synthesis of fluorophore-labeled homocystamide conjugates of human serum albumin and their use in thiol-‘click’ chemistry to prepare novel multimodal boronated albumin-based theranostic agents, which could be accumulated in tumor cells. The novelty of this work involves the development of the synthesis methodology of albumin conjugates for the imaging-guided boron neutron capture therapy combination. Herein, we suggest using thenoyltrifluoroacetone as a part of an anticancer theranostic construct: approximately 5.4 molecules of thenoyltrifluoroacetone were bound to each albumin. Along with its beneficial properties as a chemotherapeutic agent, thenoyltrifluoroacetone is a promising magnetic resonance imaging agent. The conjugation of bimodal HSA with undecahydro-closo-dodecaborate only slightly reduced human glioma cell line viability in the absence of irradiation (~30 μM of boronated albumin) but allowed for neutron capture and decreased tumor cell survival under epithermal neutron flux. The simultaneous presence of undecahydro-closo-dodecaborate and labeled amino acid residues (fluorophore dye and fluorine atoms) in the obtained HSA conjugate makes it a promising candidate for the combination imaging-guided boron neutron capture therapy.
Boron neutron capture therapy is a unique form of adjuvant cancer therapy for various malignancies including malignant gliomas. The conjugation of boron compounds and human serum albumin (HSA)—a carrier protein with a long plasma half-life—is expected to extend systemic circulation of the boron compounds and increase their accumulation in human glioma cells. We report on the synthesis of fluorophore-labeled homocystamide conjugates of human serum albumin and their use in thiol-‘click’ chemistry to prepare novel multimodal boronated albumin-based theranostic agents, which could be accumulated in tumor cells. The novelty of this work involves the development of the synthesis methodology of albumin conjugates for the imaging-guided boron neutron capture therapy combination. Herein, we suggest using thenoyltrifluoroacetone as a part of an anticancer theranostic construct: approximately 5.4 molecules of thenoyltrifluoroacetone were bound to each albumin. Along with its beneficial properties as a chemotherapeutic agent, thenoyltrifluoroacetone is a promising magnetic resonance imaging agent. The conjugation of bimodal HSA with undecahydro- closo -dodecaborate only slightly reduced human glioma cell line viability in the absence of irradiation (~30 μM of boronated albumin) but allowed for neutron capture and decreased tumor cell survival under epithermal neutron flux. The simultaneous presence of undecahydro- closo -dodecaborate and labeled amino acid residues (fluorophore dye and fluorine atoms) in the obtained HSA conjugate makes it a promising candidate for the combination imaging-guided boron neutron capture therapy.
Boron neutron capture therapy is a unique form of adjuvant cancer therapy for various malignancies including malignant gliomas. The conjugation of boron compounds and human serum albumin (HSA)-a carrier protein with a long plasma half-life-is expected to extend systemic circulation of the boron compounds and increase their accumulation in human glioma cells. We report on the synthesis of fluorophore-labeled homocystamide conjugates of human serum albumin and their use in thiol-'click' chemistry to prepare novel multimodal boronated albumin-based theranostic agents, which could be accumulated in tumor cells. The novelty of this work involves the development of the synthesis methodology of albumin conjugates for the imaging-guided boron neutron capture therapy combination. Herein, we suggest using thenoyltrifluoroacetone as a part of an anticancer theranostic construct: approximately 5.4 molecules of thenoyltrifluoroacetone were bound to each albumin. Along with its beneficial properties as a chemotherapeutic agent, thenoyltrifluoroacetone is a promising magnetic resonance imaging agent. The conjugation of bimodal HSA with undecahydro- -dodecaborate only slightly reduced human glioma cell line viability in the absence of irradiation (~30 μM of boronated albumin) but allowed for neutron capture and decreased tumor cell survival under epithermal neutron flux. The simultaneous presence of undecahydro- -dodecaborate and labeled amino acid residues (fluorophore dye and fluorine atoms) in the obtained HSA conjugate makes it a promising candidate for the combination imaging-guided boron neutron capture therapy.
Boron neutron capture therapy is a unique form of adjuvant cancer therapy for various malignancies including malignant gliomas. The conjugation of boron compounds and human serum albumin (HSA)-a carrier protein with a long plasma half-life-is expected to extend systemic circulation of the boron compounds and increase their accumulation in human glioma cells. We report on the synthesis of fluorophore-labeled homocystamide conjugates of human serum albumin and their use in thiol-'click' chemistry to prepare novel multimodal boronated albumin-based theranostic agents, which could be accumulated in tumor cells. The novelty of this work involves the development of the synthesis methodology of albumin conjugates for the imaging-guided boron neutron capture therapy combination. Herein, we suggest using thenoyltrifluoroacetone as a part of an anticancer theranostic construct: approximately 5.4 molecules of thenoyltrifluoroacetone were bound to each albumin. Along with its beneficial properties as a chemotherapeutic agent, thenoyltrifluoroacetone is a promising magnetic resonance imaging agent. The conjugation of bimodal HSA with undecahydro-closo-dodecaborate only slightly reduced human glioma cell line viability in the absence of irradiation (~30 μM of boronated albumin) but allowed for neutron capture and decreased tumor cell survival under epithermal neutron flux. The simultaneous presence of undecahydro-closo-dodecaborate and labeled amino acid residues (fluorophore dye and fluorine atoms) in the obtained HSA conjugate makes it a promising candidate for the combination imaging-guided boron neutron capture therapy.Boron neutron capture therapy is a unique form of adjuvant cancer therapy for various malignancies including malignant gliomas. The conjugation of boron compounds and human serum albumin (HSA)-a carrier protein with a long plasma half-life-is expected to extend systemic circulation of the boron compounds and increase their accumulation in human glioma cells. We report on the synthesis of fluorophore-labeled homocystamide conjugates of human serum albumin and their use in thiol-'click' chemistry to prepare novel multimodal boronated albumin-based theranostic agents, which could be accumulated in tumor cells. The novelty of this work involves the development of the synthesis methodology of albumin conjugates for the imaging-guided boron neutron capture therapy combination. Herein, we suggest using thenoyltrifluoroacetone as a part of an anticancer theranostic construct: approximately 5.4 molecules of thenoyltrifluoroacetone were bound to each albumin. Along with its beneficial properties as a chemotherapeutic agent, thenoyltrifluoroacetone is a promising magnetic resonance imaging agent. The conjugation of bimodal HSA with undecahydro-closo-dodecaborate only slightly reduced human glioma cell line viability in the absence of irradiation (~30 μM of boronated albumin) but allowed for neutron capture and decreased tumor cell survival under epithermal neutron flux. The simultaneous presence of undecahydro-closo-dodecaborate and labeled amino acid residues (fluorophore dye and fluorine atoms) in the obtained HSA conjugate makes it a promising candidate for the combination imaging-guided boron neutron capture therapy.
Author Dymova, Maya A.
Godovikova, Tatyana S.
Koroleva, Ludmila S.
Silnikov, Vladimir N.
Raskolupova, Valeria I.
Lisitskiy, Vladimir A.
Zakharova, Olga D.
Sycheva, Tatiana
Popova, Tatyana
Taskaev, Sergei
AuthorAffiliation 2 Faculty of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia; taskaev@inp.nsk.su
1 Institute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia; io197724@gmail.com (T.P.); maya.a.rot@gmail.com (M.A.D.); koroleva@niboch.nsc.ru (L.S.K.); garonna3@mail.ru (O.D.Z.); foxvo.vl@gmail.com (V.A.L.); v.raskolupova@mail.ru (V.I.R.); silnik@niboch.nsc.ru (V.N.S.)
3 Budker Institute of Nuclear Physics, SB RAS, 630090 Novosibirsk, Russia; sychevatatyanav@gmail.com
AuthorAffiliation_xml – name: 1 Institute of Chemical Biology and Fundamental Medicine, SB RAS, 630090 Novosibirsk, Russia; io197724@gmail.com (T.P.); maya.a.rot@gmail.com (M.A.D.); koroleva@niboch.nsc.ru (L.S.K.); garonna3@mail.ru (O.D.Z.); foxvo.vl@gmail.com (V.A.L.); v.raskolupova@mail.ru (V.I.R.); silnik@niboch.nsc.ru (V.N.S.)
– name: 2 Faculty of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia; taskaev@inp.nsk.su
– name: 3 Budker Institute of Nuclear Physics, SB RAS, 630090 Novosibirsk, Russia; sychevatatyanav@gmail.com
Author_xml – sequence: 1
  givenname: Tatyana
  orcidid: 0000-0002-1098-8628
  surname: Popova
  fullname: Popova, Tatyana
– sequence: 2
  givenname: Maya A.
  orcidid: 0000-0002-7281-9096
  surname: Dymova
  fullname: Dymova, Maya A.
– sequence: 3
  givenname: Ludmila S.
  orcidid: 0000-0001-9949-3703
  surname: Koroleva
  fullname: Koroleva, Ludmila S.
– sequence: 4
  givenname: Olga D.
  orcidid: 0000-0002-2054-561X
  surname: Zakharova
  fullname: Zakharova, Olga D.
– sequence: 5
  givenname: Vladimir A.
  orcidid: 0000-0003-3544-8465
  surname: Lisitskiy
  fullname: Lisitskiy, Vladimir A.
– sequence: 6
  givenname: Valeria I.
  surname: Raskolupova
  fullname: Raskolupova, Valeria I.
– sequence: 7
  givenname: Tatiana
  surname: Sycheva
  fullname: Sycheva, Tatiana
– sequence: 8
  givenname: Sergei
  orcidid: 0000-0002-5313-2563
  surname: Taskaev
  fullname: Taskaev, Sergei
– sequence: 9
  givenname: Vladimir N.
  surname: Silnikov
  fullname: Silnikov, Vladimir N.
– sequence: 10
  givenname: Tatyana S.
  surname: Godovikova
  fullname: Godovikova, Tatyana S.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34770947$$D View this record in MEDLINE/PubMed
BookMark eNp1kstu1DAUhiNURC_wAGyQJTZsBuz4kmSD1A6FqVSgUsvaOkmOpx458eBLpXkI3rmZTovaIlbHl___zi_7HBZ7ox-xKN4y-pHzhn4avMMuO4ylKpmSvHpRHDBR0hmnotl7tN4vDmNcUVoyweSrYp-LqqKNqA6KPws_-G4TEwy2RzL34yovIWEk3pBFHmAklxjyQI5dmwc7EogEyIWDZHwYSPLkIuAaApITO_geHPmeXbJ9yEvyBZ29wbAhlxMfh0gmCznxwY_kB-a0rXNYpzyZr64xwHrzunhpwEV8c1-Pil9fT6_mi9n5z29n8-PzWScanmYGJGemMVhy6GuoKfQSWlDTnrWCGcl62bUVE8oYI7Gtey5E1bZUAm8pl_yoONtxew8rvQ52gLDRHqy-O_BhqSEk2znUUxNqmMJayE4IxRukbY1SKV5xUTZmYn3esda5HbDvcEwB3BPo05vRXuulv9G1rFUj1QT4cA8I_nfGmPRgY4fOwYg-R13KphJNWTblJH3_TLryOYzTU21VigpV3wHfPU70N8rDr0-Caifogo8xoNGdTZCs3wa0TjOqt_Ol_5mvycmeOR_g__fcAgjl2K8
CitedBy_id crossref_primary_10_1016_j_apradiso_2023_110818
crossref_primary_10_37174_2587_7593_2024_7_4_19_27
crossref_primary_10_3233_JNR_220020
crossref_primary_10_3390_molecules28114369
crossref_primary_10_1002_med_21964
crossref_primary_10_1134_S1547477123040106
crossref_primary_10_3390_molecules28062672
crossref_primary_10_1134_S0020441224701707
Cites_doi 10.4155/tde-2017-0038
10.1039/C1OB06500A
10.2174/187152006776119180
10.1002/hed.20418
10.1016/0885-4505(87)90036-3
10.1088/0031-9155/53/23/021
10.2147/IJN.S210992
10.1038/nature12625
10.1016/j.radonc.2011.02.008
10.1021/ja411096m
10.1016/j.ijrobp.2010.09.057
10.1016/j.bmcl.2017.05.084
10.1002/nbm.1570
10.1038/sj.onc.1210181
10.1007/s11095-015-1718-y
10.1038/nprot.2006.339
10.1158/1078-0432.CCR-05-0035
10.1007/BF00405004
10.3171/jns.2005.103.6.1000
10.1134/S1063779619050228
10.1007/BF02699936
10.1016/S1470-2045(11)70335-7
10.1007/978-3-7091-1410-0
10.1016/S0140-6736(89)90567-9
10.1007/s10555-008-9146-7
10.1016/j.ejmp.2012.04.008
10.2337/diab.35.4.470
10.1016/S0021-9258(19)34184-5
10.1016/j.freeradbiomed.2019.01.007
10.2174/1381612821666150302115809
10.1515/pac-2017-1104
10.1016/j.ijom.2008.12.010
10.1186/s40591-016-0048-8
10.1016/j.rpor.2014.11.004
10.1007/978-1-4757-9567-7
10.3390/biomedicines9010074
10.1007/s11060-008-9699-x
10.1016/j.jconrel.2016.07.017
10.1021/acsomega.8b01729
10.1016/j.apsb.2018.03.010
10.7150/thno.19365
10.1016/j.apradiso.2009.03.103
10.1016/j.bbrc.2016.12.176
10.1016/S1357-2725(99)00090-4
10.1021/jp408304e
10.1021/mp500439c
10.1016/S0277-5387(00)00293-X
10.1007/978-3-642-31334-9
10.3109/1061186X.2012.729214
10.3390/molecules24193609
10.1016/j.jconrel.2011.07.031
10.1093/jrr/rrx071
10.1016/j.bcp.2012.01.008
10.1016/j.apradiso.2004.05.059
10.1002/ejic.201700578
10.1007/s12149-019-01347-8
10.21147/j.issn.1000-9604.2016.06.10
10.1021/acs.chemrev.5b00300
10.1080/14686996.2019.1586051
10.1039/C9OB00584F
10.1186/s13046-019-1309-6
10.1126/sciadv.aaz1722
10.1016/j.cis.2017.06.012
10.1016/0022-1759(83)90303-4
10.2147/IJN.S118661
10.1021/cr9003538
10.1016/j.bmc.2015.09.043
10.1039/C5CS00158G
10.1016/j.apradiso.2009.03.019
10.1016/j.jconrel.2011.09.069
10.1016/S0945-053X(00)00133-5
10.1016/j.molmed.2015.01.001
ContentType Journal Article
Copyright 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2021 by the authors. 2021
Copyright_xml – notice: 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2021 by the authors. 2021
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.3390/molecules26216537
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
ProQuest Central
ProQuest One
ProQuest Central Korea
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef


MEDLINE
Publicly Available Content Database
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
EISSN 1420-3049
ExternalDocumentID oai_doaj_org_article_fe20f16e845c44639e0b8e566373429f
PMC8586956
34770947
10_3390_molecules26216537
Genre Journal Article
GrantInformation_xml – fundername: Russian Science Foundation
  grantid: 19-74-20123
GroupedDBID ---
0R~
123
2WC
53G
5VS
7X7
88E
8FE
8FG
8FH
8FI
8FJ
A8Z
AADQD
AAFWJ
AAHBH
AAYXX
ABDBF
ABUWG
ACGFO
ACIWK
ACPRK
ACUHS
AEGXH
AENEX
AFKRA
AFPKN
AFRAH
AFZYC
AIAGR
ALIPV
ALMA_UNASSIGNED_HOLDINGS
BENPR
BPHCQ
BVXVI
CCPQU
CITATION
CS3
D1I
DIK
DU5
E3Z
EBD
EMOBN
ESX
FYUFA
GROUPED_DOAJ
GX1
HH5
HMCUK
HYE
HZ~
I09
IAO
IHR
ITC
KQ8
LK8
M1P
MODMG
O-U
O9-
OK1
P2P
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RPM
SV3
TR2
TUS
UKHRP
~8M
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c493t-fa531f9fe23ad8a80ad5aba6e231b41f51d5cb7146fff5eb8d3447bb05a3b0353
IEDL.DBID DOA
ISSN 1420-3049
IngestDate Wed Aug 27 01:05:51 EDT 2025
Thu Aug 21 14:08:16 EDT 2025
Thu Jul 10 19:24:01 EDT 2025
Fri Jul 25 09:31:07 EDT 2025
Thu Apr 03 07:03:15 EDT 2025
Tue Jul 01 03:12:00 EDT 2025
Thu Apr 24 22:53:55 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 21
Keywords conjugate
boron neutron capture therapy
thenoyltrifluoroacetone
colony forming assay
boronated albumin theranostic
irradiated by epithermal neutron flux
in vitro efficacy evaluation
boron delivery agents
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c493t-fa531f9fe23ad8a80ad5aba6e231b41f51d5cb7146fff5eb8d3447bb05a3b0353
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-3544-8465
0000-0002-1098-8628
0000-0001-9949-3703
0000-0002-2054-561X
0000-0002-7281-9096
0000-0002-5313-2563
OpenAccessLink https://doaj.org/article/fe20f16e845c44639e0b8e566373429f
PMID 34770947
PQID 2596046856
PQPubID 2032355
ParticipantIDs doaj_primary_oai_doaj_org_article_fe20f16e845c44639e0b8e566373429f
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8586956
proquest_miscellaneous_2597492292
proquest_journals_2596046856
pubmed_primary_34770947
crossref_citationtrail_10_3390_molecules26216537
crossref_primary_10_3390_molecules26216537
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20211029
PublicationDateYYYYMMDD 2021-10-29
PublicationDate_xml – month: 10
  year: 2021
  text: 20211029
  day: 29
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Molecules (Basel, Switzerland)
PublicationTitleAlternate Molecules
PublicationYear 2021
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Sato (ref_77) 2018; 59
Xu (ref_62) 2015; 21
Ariyoshi (ref_9) 2007; 18
Kulluru (ref_27) 2013; 21
Eriksson (ref_68) 1991; 34
ref_56
Nakagawa (ref_4) 2003; 62
Kreiner (ref_75) 2016; 21
ref_53
Bannunah (ref_73) 2014; 11
Brekken (ref_33) 2001; 19
An (ref_55) 2017; 7
Chubarov (ref_48) 2015; 23
Mbiya (ref_71) 2013; 117
ref_18
Elsadek (ref_51) 2012; 157
Pisanti (ref_69) 1987; 37
ref_16
Caspersen (ref_52) 2017; 8
Kikuchi (ref_37) 2016; 237
Kawasaki (ref_22) 2017; 483
Bhushan (ref_26) 2017; 246
Frigell (ref_42) 2014; 136
Li (ref_59) 2019; 38
Nakamura (ref_25) 2012; 10
Zhao (ref_45) 2018; 8
Brooks (ref_21) 2016; 116
Elzoghby (ref_29) 2012; 157
Kouros (ref_34) 1999; 31
Kato (ref_13) 2004; 61
ref_67
Zaboronok (ref_78) 2017; 11
Hu (ref_63) 2012; 83
Yong (ref_17) 2016; 28
Bregadze (ref_64) 2006; 6
Shi (ref_36) 2007; 26
Mosmann (ref_72) 1983; 65
Nakamura (ref_39) 2018; 90
Sivaev (ref_80) 2000; 19
Ishiwata (ref_43) 2019; 33
Kogan (ref_30) 2019; 14
Louie (ref_46) 2010; 110
Papaccio (ref_70) 1986; 35
Barnett (ref_47) 2011; 24
Larsen (ref_31) 2016; 4
Janatova (ref_66) 1968; 243
Taskaev (ref_76) 2019; 50
Franken (ref_79) 2006; 1
Fuentes (ref_58) 2019; 136
Yhee (ref_28) 2015; 21
Fasano (ref_50) 2008; 53
Lisitskiy (ref_49) 2017; 27
Barth (ref_2) 2018; 38
Kato (ref_14) 2009; 67
Sousa (ref_32) 2014; 35
Ishii (ref_38) 2019; 17
Mishima (ref_15) 1989; 2
Liu (ref_54) 2016; 45
Nomoto (ref_23) 2020; 6
Miyatake (ref_5) 2005; 103
Kimura (ref_10) 2009; 38
Savolainen (ref_44) 2013; 29
ref_41
Kankaanranta (ref_7) 2011; 99
Turner (ref_61) 2012; 13
Hiratsuka (ref_19) 2018; 38
Podhajcer (ref_35) 2008; 27
Barth (ref_1) 2005; 11
Barth (ref_3) 2018; 38
Miyatake (ref_6) 2009; 91
Wanigasekara (ref_57) 2018; 3
Kimura (ref_11) 2009; 67
Sato (ref_40) 2017; 2017
Burrell (ref_60) 2013; 7467
Luderer (ref_20) 2015; 32
Yoneoka (ref_24) 2019; 20
Aihara (ref_12) 2006; 28
Kankaanranta (ref_8) 2012; 82
Ravasco (ref_65) 2018; 24
Martucci (ref_74) 2016; 11
References_xml – volume: 8
  start-page: 511
  year: 2017
  ident: ref_52
  article-title: Albumin-based drug delivery using cysteine 34 chemical conjugates–important considerations and requirements
  publication-title: Ther. Deliv.
  doi: 10.4155/tde-2017-0038
– volume: 38
  start-page: 35
  year: 2018
  ident: ref_3
  article-title: Boron delivery agents for neutron capture therapy of cancer
  publication-title: Cancer Commun.
– volume: 10
  start-page: 1374
  year: 2012
  ident: ref_25
  article-title: Design and synthesis of fluorescence-labeled closo-dodecaborate lipid: Its liposome formation and in vivo imaging targeting of tumors for boron neutron capture therapy
  publication-title: Org. Biomol. Chem.
  doi: 10.1039/C1OB06500A
– volume: 6
  start-page: 75
  year: 2006
  ident: ref_64
  article-title: Polyhedral boron compounds as potential diagnostic and therapeutic antitumor agents
  publication-title: Anti-Cancer Agents Med. Chem.
  doi: 10.2174/187152006776119180
– volume: 28
  start-page: 850
  year: 2006
  ident: ref_12
  article-title: First clinical case of boron neutron capture therapy for head and neck malignancies using 18F-BPA PET
  publication-title: Head Neck
  doi: 10.1002/hed.20418
– volume: 37
  start-page: 265
  year: 1987
  ident: ref_69
  article-title: Influence of acetyl homocysteine thiolactone on erythrocyte superoxide dismutase activity
  publication-title: Biochem. Med. Metab. Biol.
  doi: 10.1016/0885-4505(87)90036-3
– volume: 53
  start-page: 6979
  year: 2008
  ident: ref_50
  article-title: In vivo F-19 MRI and F-19 MRS of F-19-labelled borophenylalanine-fructose complex on a C6 rat glioma model to optimize boron neutron capture therapy (BNCT)
  publication-title: Phys. Med. Biol.
  doi: 10.1088/0031-9155/53/23/021
– volume: 14
  start-page: 6387
  year: 2019
  ident: ref_30
  article-title: Capping gold nanoparticles with albumin to improve their biomedical properties
  publication-title: Int. J. Nanomed.
  doi: 10.2147/IJN.S210992
– volume: 7467
  start-page: 338
  year: 2013
  ident: ref_60
  article-title: The causes and consequences of genetic heterogeneity in cancer evolution
  publication-title: Nature
  doi: 10.1038/nature12625
– volume: 99
  start-page: 98
  year: 2011
  ident: ref_7
  article-title: Boron neutron capture therapy (BNCT) followed by intensity modulated chemoradiotherapy as primary treatment of large head and neck cancer with intracranial involvement
  publication-title: Radiother. Oncol.
  doi: 10.1016/j.radonc.2011.02.008
– volume: 136
  start-page: 449
  year: 2014
  ident: ref_42
  article-title: 68Ga-labeled gold glyconanoparticles for exploring blood-brain barrier permeability: Preparation, biodistribution studies, and improved brain uptake via neuropeptide conjugation
  publication-title: J. Am. Chem. Soc.
  doi: 10.1021/ja411096m
– volume: 11
  start-page: 6
  year: 2017
  ident: ref_78
  article-title: Boron-neutron capture therapy in Russia: Preclinical evaluation of efficacy and perspectives of its application in neurooncology
  publication-title: New Armen. Med. J.
– volume: 82
  start-page: e67
  year: 2012
  ident: ref_8
  article-title: Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: Final analysis of a phase I/II trial
  publication-title: Int. J. Radiat. Oncol. Biol. Phys.
  doi: 10.1016/j.ijrobp.2010.09.057
– volume: 27
  start-page: 3925
  year: 2017
  ident: ref_49
  article-title: Multifunctional human serum albumin-therapeutic nucleotide conjugate with redox and pH-sensitive drug release mechanism for cancer theranostics
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2017.05.084
– volume: 24
  start-page: 114
  year: 2011
  ident: ref_47
  article-title: Fluorine (19F) MRS and MRI in biomedicine
  publication-title: NMR Biomed.
  doi: 10.1002/nbm.1570
– volume: 26
  start-page: 4084
  year: 2007
  ident: ref_36
  article-title: Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1210181
– volume: 32
  start-page: 2824
  year: 2015
  ident: ref_20
  article-title: Advancements in tumor targeting strategies for boron neutron capture therapy
  publication-title: Pharm. Res.
  doi: 10.1007/s11095-015-1718-y
– volume: 1
  start-page: 2315
  year: 2006
  ident: ref_79
  article-title: Clonogenic assay of cells in vitro
  publication-title: Nat. Protoc.
  doi: 10.1038/nprot.2006.339
– volume: 11
  start-page: 3987
  year: 2005
  ident: ref_1
  article-title: Boron neutron capture therapy of cancer: Current status and future prospects
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-05-0035
– volume: 34
  start-page: 325
  year: 1991
  ident: ref_68
  article-title: Protection by free oxygen radical scavenging enzymes against glucose-induced embryonic malformations in vitro
  publication-title: Diabetologia
  doi: 10.1007/BF00405004
– volume: 103
  start-page: 1000
  year: 2005
  ident: ref_5
  article-title: Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: An efficacy study based on findings on neuroimages
  publication-title: J. Neurosurg.
  doi: 10.3171/jns.2005.103.6.1000
– volume: 50
  start-page: 569
  year: 2019
  ident: ref_76
  article-title: Development of an accelerator-based epithermal neutron source for boron neutron capture therapy
  publication-title: Phys. Part. Nucl.
  doi: 10.1134/S1063779619050228
– volume: 62
  start-page: 87
  year: 2003
  ident: ref_4
  article-title: Clinical review of the Japanese experience with boron neutron capture therapy and a proposed strategy using epithermal neutron beams
  publication-title: J. Neurooncol.
  doi: 10.1007/BF02699936
– volume: 13
  start-page: 178
  year: 2012
  ident: ref_61
  article-title: Genetic heterogeneity and cancer drug resistance
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(11)70335-7
– ident: ref_67
  doi: 10.1007/978-3-7091-1410-0
– volume: 18
  start-page: 861
  year: 2007
  ident: ref_9
  article-title: Boron neuron capture therapy using epithermal neutrons for recurrent cancer in the oral cavity and cervical lymph node metastasis
  publication-title: Oncol. Rep.
– volume: 2
  start-page: 388
  year: 1989
  ident: ref_15
  article-title: Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking 10B-compound
  publication-title: Lancet
  doi: 10.1016/S0140-6736(89)90567-9
– volume: 38
  start-page: 1
  year: 2018
  ident: ref_19
  article-title: Boron neutron capture therapy for vulvar melanoma and extramammary Paget’s disease of the genital regions with curative clinical responses
  publication-title: Chin. J. Cancer
– volume: 27
  start-page: 691
  year: 2008
  ident: ref_35
  article-title: The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host
  publication-title: Cancer Metastasis Rev.
  doi: 10.1007/s10555-008-9146-7
– volume: 29
  start-page: 233
  year: 2013
  ident: ref_44
  article-title: Boron neutron capture therapy (BNCT) in Finland: Technological and physical prospects after 20 years of experiences
  publication-title: Phys. Med.
  doi: 10.1016/j.ejmp.2012.04.008
– volume: 35
  start-page: 470
  year: 1986
  ident: ref_70
  article-title: Acetyl-homocysteine-thiolactone-induced increase of superoxide dismutase counteracts the effect of subdiabetogenic doses of streptozocin
  publication-title: Diabetes
  doi: 10.2337/diab.35.4.470
– volume: 243
  start-page: 3612
  year: 1968
  ident: ref_66
  article-title: The heterogeneity of bovine albumin with respect to sulfhydryl and dimer content
  publication-title: J. Biol. Chem.
  doi: 10.1016/S0021-9258(19)34184-5
– volume: 35
  start-page: 3435
  year: 2014
  ident: ref_32
  article-title: Blood protein coating of gold nanoparticles as potential tool for organ targeting
  publication-title: Biomaterials
– volume: 136
  start-page: 172
  year: 2019
  ident: ref_58
  article-title: Regulation of mitochondrial function as a promising target in platelet activation-related diseases
  publication-title: Free Radic. Biol. Med.
  doi: 10.1016/j.freeradbiomed.2019.01.007
– volume: 21
  start-page: 1889
  year: 2015
  ident: ref_28
  article-title: Molecular imaging and targeted drug delivery using albumin-based nanoparticles
  publication-title: Curr. Pharm. Des.
  doi: 10.2174/1381612821666150302115809
– volume: 90
  start-page: 745
  year: 2018
  ident: ref_39
  article-title: closo-Dodecaborate-conjugated human serum albumins: Preparation and in vivo selective boron delivery to tumor
  publication-title: Pure Appl. Chem.
  doi: 10.1515/pac-2017-1104
– volume: 38
  start-page: 293
  year: 2009
  ident: ref_10
  article-title: Boron neutron capture therapy for papillary cystadenocarcinoma in the upper lip: A case report
  publication-title: Int. J. Oral. Maxillofac. Surg.
  doi: 10.1016/j.ijom.2008.12.010
– volume: 4
  start-page: 1
  year: 2016
  ident: ref_31
  article-title: Albumin-based drug delivery: Harnessing nature to cure disease
  publication-title: Mol. Cell. Ther.
  doi: 10.1186/s40591-016-0048-8
– volume: 21
  start-page: 95
  year: 2016
  ident: ref_75
  article-title: Present status of accelerator-based BNCT
  publication-title: Rep. Pract. Oncol. Radiother.
  doi: 10.1016/j.rpor.2014.11.004
– ident: ref_16
  doi: 10.1007/978-1-4757-9567-7
– ident: ref_56
  doi: 10.3390/biomedicines9010074
– volume: 91
  start-page: 199
  year: 2009
  ident: ref_6
  article-title: Survival benefit of boron neutron capture therapy for recurrent malignant gliomas
  publication-title: J. Neurooncol.
  doi: 10.1007/s11060-008-9699-x
– volume: 237
  start-page: 160
  year: 2016
  ident: ref_37
  article-title: Maleimide-functionalized closo-dodecaborate albumin conjugates (MID-AC): Unique ligation at cysteine and lysine residues enables efficient boron delivery to tumor for neutron capture therapy
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2016.07.017
– ident: ref_53
– volume: 3
  start-page: 14229
  year: 2018
  ident: ref_57
  article-title: Arginine-Selective chemical labeling approach for identification and enrichment of reactive arginine residues in proteins
  publication-title: ACS Omega
  doi: 10.1021/acsomega.8b01729
– volume: 8
  start-page: 320
  year: 2018
  ident: ref_45
  article-title: Recent developments in multimodality fluorescence imaging probes
  publication-title: Acta Pharm. Sin. B
  doi: 10.1016/j.apsb.2018.03.010
– volume: 7
  start-page: 3667
  year: 2017
  ident: ref_55
  article-title: Strategies for preparing albumin-based nanoparticles for multifunctional bioimaging and drug delivery
  publication-title: Theranostics
  doi: 10.7150/thno.19365
– volume: 67
  start-page: S37
  year: 2009
  ident: ref_14
  article-title: Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies
  publication-title: Appl. Radiat. Isot.
  doi: 10.1016/j.apradiso.2009.03.103
– volume: 483
  start-page: 147
  year: 2017
  ident: ref_22
  article-title: Intracellular delivery and passive tumor targeting of a self-assembled nanogel containing carborane clusters for boron neutron capture therapy
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2016.12.176
– volume: 31
  start-page: 1363
  year: 1999
  ident: ref_34
  article-title: SPARC (osteonectin/BM-40)
  publication-title: Int. J. Biochem. Cell Biol.
  doi: 10.1016/S1357-2725(99)00090-4
– volume: 117
  start-page: 13059
  year: 2013
  ident: ref_71
  article-title: Oxyhalogen-sulfur chemistry: Kinetics and mechanism of oxidation of N-acetyl homocysteine thiolactone by acidified bromate and aqueous bromine
  publication-title: J. Phys. Chem. A
  doi: 10.1021/jp408304e
– volume: 11
  start-page: 4363
  year: 2014
  ident: ref_73
  article-title: Mechanisms of nanoparticle internalization and transport across an intestinal epithelial cell model: Effect of size and surface charge
  publication-title: Mol. Pharm.
  doi: 10.1021/mp500439c
– volume: 19
  start-page: 627
  year: 2000
  ident: ref_80
  article-title: Synthesis of oxonium derivatives of the dodecahydro-closo-dodecaborate anion [B12H12]2−. Tetramethylene oxonium derivative of [B12H12]2− as a convenient precursor for the synthesis of functional compounds for boron neutron capture therapy
  publication-title: Polyhedron
  doi: 10.1016/S0277-5387(00)00293-X
– ident: ref_18
  doi: 10.1007/978-3-642-31334-9
– volume: 21
  start-page: 77
  year: 2013
  ident: ref_27
  article-title: Formulation development of albumin based theranostic nanoparticles as a potential delivery system for tumor targeting
  publication-title: J. Drug Target.
  doi: 10.3109/1061186X.2012.729214
– ident: ref_41
  doi: 10.3390/molecules24193609
– volume: 24
  start-page: 1
  year: 2018
  ident: ref_65
  article-title: Bioconjugation with maleimides: A useful tool for chemical biology
  publication-title: Chem. Eur. J.
– volume: 157
  start-page: 168
  year: 2012
  ident: ref_29
  article-title: Albumin-based nanoparticles as potential controlled release drug delivery systems
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2011.07.031
– volume: 59
  start-page: 101
  year: 2018
  ident: ref_77
  article-title: Radiobiological response of U251MG, CHO-K1 and V79 cell lines to accelerator-based boron neutron capture therapy
  publication-title: J. Radiat. Res.
  doi: 10.1093/jrr/rrx071
– volume: 83
  start-page: 1104
  year: 2012
  ident: ref_63
  article-title: Nanoparticle-based combination therapy toward overcoming drug resistance in cancer
  publication-title: Biochem. Pharm.
  doi: 10.1016/j.bcp.2012.01.008
– volume: 61
  start-page: 1069
  year: 2004
  ident: ref_13
  article-title: Effectiveness of BNCT for recurrent head and neck malignancies
  publication-title: Appl. Radiat. Isot.
  doi: 10.1016/j.apradiso.2004.05.059
– volume: 2017
  start-page: 4406
  year: 2017
  ident: ref_40
  article-title: Development of albumin-closo-dodecaborate conjugates as boron carriers for neutron-capture therapy by Ru(bpy)3-photocatalyzed modification of tyrosine
  publication-title: Eur. J. Inorg. Chem.
  doi: 10.1002/ejic.201700578
– volume: 33
  start-page: 223
  year: 2019
  ident: ref_43
  article-title: 4-Borono-2-18F-fluoro-L-phenylalanine PET for boron neutron capture therapy-oriented diagnosis: Overview of a quarter century of research
  publication-title: Ann. Nucl. Med.
  doi: 10.1007/s12149-019-01347-8
– volume: 28
  start-page: 634
  year: 2016
  ident: ref_17
  article-title: Boron neutron capture therapy for malignant melanoma: First clinical case report in China
  publication-title: Chin. J. Cancer Res.
  doi: 10.21147/j.issn.1000-9604.2016.06.10
– volume: 116
  start-page: 1375
  year: 2016
  ident: ref_21
  article-title: Synthesis and applications of boronic acid-containing polymers: From materials to medicine
  publication-title: Chem. Rev.
  doi: 10.1021/acs.chemrev.5b00300
– volume: 20
  start-page: 291
  year: 2019
  ident: ref_24
  article-title: Boron-incorporating hemagglutinating virus of Japan envelope (HVJ-E) nanomaterial in boron neutron capture therapy
  publication-title: Sci. Technol. Adv. Mater.
  doi: 10.1080/14686996.2019.1586051
– volume: 17
  start-page: 5496
  year: 2019
  ident: ref_38
  article-title: Design of S-S bond containing maleimide-conjugated closo-dodecaborate (SSMID): Identification of unique modification sites on albumin and investigation of intracellular uptake
  publication-title: Org. Biomol. Chem.
  doi: 10.1039/C9OB00584F
– volume: 38
  start-page: 327
  year: 2019
  ident: ref_59
  article-title: Effects of hyperglycemia on the progression of tumor diseases
  publication-title: J. Exp. Clin. Cancer Res.
  doi: 10.1186/s13046-019-1309-6
– volume: 6
  start-page: eaaz1722
  year: 2020
  ident: ref_23
  article-title: Poly(vinyl alcohol) boosting therapeutic potential of p-boronophenylalanine in neutron capture therapy by modulating metabolism
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.aaz1722
– volume: 246
  start-page: 13
  year: 2017
  ident: ref_26
  article-title: Impact of albumin based approaches in nanomedicine: Imaging, targeting and drug delivery
  publication-title: Adv. Colloid Interface Sci.
  doi: 10.1016/j.cis.2017.06.012
– volume: 65
  start-page: 55
  year: 1983
  ident: ref_72
  article-title: Rapid colorimetric assay for cellular growth and survival–application to proliferation and cyto-toxicity assays
  publication-title: J. Immunol. Methods
  doi: 10.1016/0022-1759(83)90303-4
– volume: 11
  start-page: 6089
  year: 2016
  ident: ref_74
  article-title: Nanoparticle-based strategy for personalized B-cell lymphoma therapy
  publication-title: Int. J. Nanomed.
  doi: 10.2147/IJN.S118661
– volume: 110
  start-page: 3146
  year: 2010
  ident: ref_46
  article-title: Multimodality imaging probes: Design and challenges
  publication-title: Chem. Rev.
  doi: 10.1021/cr9003538
– volume: 23
  start-page: 6943
  year: 2015
  ident: ref_48
  article-title: Design of protein homocystamides with enhanced tumor uptake properties for 19F magnetic resonance imaging
  publication-title: Bioorg. Med. Chem.
  doi: 10.1016/j.bmc.2015.09.043
– volume: 45
  start-page: 1432
  year: 2016
  ident: ref_54
  article-title: Simple bioconjugate chemistry serves great clinical advances: Albumin as a versatile platform for diagnosis and precision therapy
  publication-title: Chem. Soc. Rev.
  doi: 10.1039/C5CS00158G
– volume: 67
  start-page: S47
  year: 2009
  ident: ref_11
  article-title: Boron neutron capture therapy for recurrent oral cancer and metastasis of cervical lymph node
  publication-title: Appl. Radiat. Isot.
  doi: 10.1016/j.apradiso.2009.03.019
– volume: 38
  start-page: 36
  year: 2018
  ident: ref_2
  article-title: A realistic appraisal of boron neutron capture therapy as a cancer treatment modality
  publication-title: Cancer Commun.
– volume: 157
  start-page: 4
  year: 2012
  ident: ref_51
  article-title: Impact of albumin on drug delivery—New applications on the horizon
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2011.09.069
– volume: 19
  start-page: 815
  year: 2001
  ident: ref_33
  article-title: Mini review SPARC, a matricellular protein: At the crossroads of cell matrix SPARC, a matricellular protein: At the crossroads of cell matrix communication
  publication-title: Matrix Biol.
  doi: 10.1016/S0945-053X(00)00133-5
– volume: 21
  start-page: 223
  year: 2015
  ident: ref_62
  article-title: Cancer nanomedicine: From targeted delivery to combination therapy
  publication-title: Trends Mol. Med.
  doi: 10.1016/j.molmed.2015.01.001
SSID ssj0021415
Score 2.3891847
Snippet Boron neutron capture therapy is a unique form of adjuvant cancer therapy for various malignancies including malignant gliomas. The conjugation of boron...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 6537
SubjectTerms Antineoplastic Agents - chemical synthesis
Antineoplastic Agents - chemistry
Antineoplastic Agents - therapeutic use
Biodistribution
Boron
Boron Compounds - chemical synthesis
Boron Compounds - chemistry
Boron Compounds - therapeutic use
boron delivery agents
Boron Neutron Capture Therapy
boronated albumin theranostic
Brain cancer
Cancer therapies
Cell Line, Tumor
Cell Proliferation - drug effects
Cell Survival - drug effects
Chemotherapy
conjugate
Cytotoxicity
Drug Delivery Systems
Drug Screening Assays, Antitumor
Drugs
Fluorine
Glioma
Homocysteine - analogs & derivatives
Homocysteine - chemistry
Humans
Hyperglycemia
in vitro efficacy evaluation
Magnetic resonance imaging
Molecular Structure
Proteins
Radiation
Serum Albumin, Human - chemistry
thenoyltrifluoroacetone
Tumors
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagHOCCeBMoaJA4IUVN4tiOT4hdqFZIVD200t4i27HLVrvJskkO_RH9zx072W0XUI9JHMXJ2DPfPPINIZ8ZrajkUsYK0UGcp6gHZUJV7ITRGhGHEyHR_uuEz87zn3M2HwNu7VhWudWJQVFXjfEx8iOE6Rx9uYLxr-s_se8a5bOrYwuNh-SRpy7zJV1ifutwpWidhkwmRdf-aDU0nLVtxrOUM9_6_I4tCpT9_8OZf5dL3rE_x8_I0xE4wrdB0s_JA1u_II-n235tL8n1rFk15grR3mpRWZg29WXvY2QtNA5CrB5QMfQrCFH5RQ2qBQWnS9V53ApdA6cb6-vRYYLyq_BZ4efcatNfwHe79PUbVzASnAPeAhNPfgAntvfRdJiqtU9GwNlAU_CKnB__OJvO4rHZQmxySbvYKdyNTjqbUVUVqkhUxZRWHI9TnaeOpRUzWqBidc4xq4vKcwVqnTBFdUIZfU0O6qa2bwlQpjVPXJEqZnORG22cM0oobnTunDIRSbafvTQjE7lviLEs0SPxkir_kVREvuxuWQ80HPcNnnhZ7gZ6Bu1wotlclOOGLPFFE5dyW-TMoEtMpU10YRHcUkHRRruIHG5XQjlu67a8XYQR-bS7jHL2WRZV26YPY0Qus0xmEXkzLJzdTGguBPrTOEOxt6T2prp_pV78DqTfBSs4-rLv7p_We_Ik80U3aFwzeUgOuk1vPyBq6vTHsDVuANwAHdM
  priority: 102
  providerName: ProQuest
Title Homocystamide Conjugates of Human Serum Albumin as a Platform to Prepare Bimodal Multidrug Delivery Systems for Boron Neutron Capture Therapy
URI https://www.ncbi.nlm.nih.gov/pubmed/34770947
https://www.proquest.com/docview/2596046856
https://www.proquest.com/docview/2597492292
https://pubmed.ncbi.nlm.nih.gov/PMC8586956
https://doaj.org/article/fe20f16e845c44639e0b8e566373429f
Volume 26
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZgOcAF8SawVIPECSnaJH7muC1bKiSqCu1KvUW2Y0NXbbJqm8P-CP7zjpO0agHBhUukxLYy8YznYU--IeQDpyXNRZ7HGr2DmKWoB_OE6thLawx6HF62B-1fp2Jyxb7M-fyg1FfICevggbuJO_MuS3wqnGLcYuhCc5cY5dAJoZKiLvVB-6LN2wVTfaiVol3qzjApBvVnq67UrNtkIksFD0XPD6xQC9b_Jw_z10TJA8szfkIe9y4jnHekPiX3XPWMPBztKrU9Jz8n9aq2t-jnrRalg1FdXTdhd2wDtYd2lx5QJTQraPfjFxXoDWiYLfU2eKywrWG2diETHYbIuRLf1f6WW66b7_DJLUPmxi300OaAQ2AYYA9g6pqwjw4jfROOIeCyAyh4Qa7GF5ejSdyXWYgty-k29hrXoc9xoqkulVaJLrk2WuB9aljqeVpyaySqVO89d0aVASXQmIRrahLK6UtyUtWVe02AcmNE4lWquWOSWWO9t1pqYQ3zXtuIJLtpL2yPQR5KYSwLjEUCp4rfOBWRj_shNx0Ax986DwMv9x0Ddnb7ACWq6CWq-JdEReR0JwlFv6A3BUaJImFCcRGR9_tm5HM4X9GVq5u2j2R5luVZRF51grOnhDIpMZJGCuWRSB2RetxSLX60cN-KK4FR7Jv_8W1vyaMsJOWg8c3yU3KyXTfuHXpVWzMg9-Vc4lWNPw_Ig-HFdPZt0C6qO3wkKME
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqcigXxJtAASPBBSlqEj-SHBBityxb2q562Eq9Bduxy6LdZNlNhPZH8Ff4jYydB11AvfWY2FHszGT8jWc8H0KvGclJytPUF4AOfBqCHUwDInwTKykBcZjYBdpPJ3x8Tj9fsIsd9Ks7C2PTKjub6Ax1Xiq7R34AMJ2DL5cw_n753besUTa62lFoNGpxrDc_wGVbvzs6BPm-iaLRx-lw7LesAr6iKal8I0DtTGp0RESeiCQQORNScLgOJQ0NC3OmZAwWxBjDtExyWxRPyoAJIgPHEgEm_xYlMEd7Mn30qXfwQlgNm8gpNAYHi4bgVq8jHoWcWar1K2ufowj4H679Oz3zyno3uovutEAVf2g06x7a0cV9tDfs-OEeoJ_jclGqDaDLxSzXeFgW32q7J7fGpcEuNoDBENUL7KIAswKLNRb4bC4qi5NxVeKzlbb573gA-pLDu9xh4HxVX-JDPbf5IhvcFlTH8Age2GILeKJru3uPh2Jpgx942pRFeIjOb0QMj9BuURb6CcKESckDk4SCaRpTJZUxSsSCK0mNEcpDQffZM9VWPrcEHPMMPCArqewfSXnobf_Isin7cV3ngZVl39FW7HY3ytVl1hqADCYamJDrhDIFLjhJdSATDWCaxAQwgfHQfqcJWWtG1tkfpffQq74Z5GyjOqLQZe36xDSNojTy0ONGcfqREBrH4L_DCOMtldoa6nZLMfvqiownLOHgOz-9flgv0d54enqSnRxNjp-h25FN-IGFPUr30W61qvVzQGyVfOF-E4y-3PR_-RvMJFwt
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NjtMwELZWiwRcEP8UFjASXJCiJnFsxweEaEvVZaHqYVfqLdiOvRS1SWkboT4EL8TTMXaS7hbQ3vaYxFGczI-_8UzmQ-g1JTkRTIhAAjoIkgj8oAiJDCzXSgHisNwn2r-M2egs-TSl0wP0u_0XxpVVtj7RO-q81G6PvAswnUEsl1LWtU1ZxGQwfL_8ETgGKZdpbek0ahU5MdufEL6t3x0PQNZv4nj48bQ_ChqGgUAngmwCK0EFrbAmJjJPZRrKnEolGRxHKoksjXKqFQdvYq2lRqW5a5CnVEglUaFnjAD3f4MTGjkb49OLYC-ClbHOohIiwu6iJrs165jFEaOOdv3SOujpAv6Hcf8u1by09g3vojsNaMUfai27hw5McR_d6rdccQ_Qr1G5KPUWkOZilhvcL4vvldufW-PSYp8nwOCUqgX2GYFZgeUaSzyZy43DzHhT4snKuFp43APdyeFZ_sfgfFWd44GZu9qRLW6aq2O4Bfdc4wU8NpXbycd9uXSJEHxat0h4iM6uRQyP0GFRFuYJwoQqxUKbRpKahCdaaWu15JJplVgrdQeF7WfPdNMF3ZFxzDOIhpyksn8k1UFvd7cs6xYgVw3uOVnuBrru3f5EuTrPGmeQwYuGNmImTaiGcJwIE6rUALAmnAA-sB101GpC1riUdXZhAB30ancZ5OwyPLIwZeXH8ETEsYg76HGtOLuZkIRziOVhhnxPpfamun-lmH3zDcdTmjKIo59ePa2X6CZYZPb5eHzyDN2OXe0PrPGxOEKHm1VlngN426gX3kow-nrdZvkHYfJgWg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Homocystamide+Conjugates+of+Human+Serum+Albumin+as+a+Platform+to+Prepare+Bimodal+Multidrug+Delivery+Systems+for+Boron+Neutron+Capture+Therapy&rft.jtitle=Molecules+%28Basel%2C+Switzerland%29&rft.au=Popova%2C+Tatyana&rft.au=Dymova%2C+Maya+A&rft.au=Koroleva%2C+Ludmila+S&rft.au=Zakharova%2C+Olga+D&rft.date=2021-10-29&rft.issn=1420-3049&rft.eissn=1420-3049&rft.volume=26&rft.issue=21&rft_id=info:doi/10.3390%2Fmolecules26216537&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1420-3049&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1420-3049&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1420-3049&client=summon